The PrP-like Protein Doppel Binds Copper*

Kefeng QinDagger , Janaky CoomaraswamyDagger , Peter MastrangeloDagger , Ying Yang§, Stan Lugowski, Chris Petromilli||, Stanley B. Prusiner||, Paul E. FraserDagger **, Jonathan M. GoldbergDagger Dagger , Avijit Chakrabartty**, and David WestawayDagger §§¶¶

From the Dagger  Centre for Research in Neurodegenerative Diseases, the § Mass Spectrometry Laboratory, Molecular Medicine Research Centre, the  Institute for Biomaterials and Biomechanical Engineering, the ** Department of Medical Biophysics, and the §§ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5S 3H2, Canada, the || Institute for Neurodegenerative Diseases, University of California, San Francisco, California 94143, and the Dagger Dagger  Boston Biomedical Research Institute, Watertown, Massachusetts 02472

Received for publication, October 23, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Doppel (Dpl) is a glycosylphosphatidylinositol-anchored protein expressed in the testis. It exhibits 26% sequence identity with the prion protein (PrP) but lacks the octarepeat region implicated as the major copper-binding domain. Contrary to expectations, Cu(II) induced a 26% reduction in the intrinsic fluorescence of Dpl(27-154) and a calculated Kd for a single-site model of 0.16 ± 0.08 µM. Other metals had minimal effects on fluorescence quenching. Matrix-assisted laser desorption ionization mass spectrometry of a Dpl peptide revealed binding of copper (but not other metals) to the helical alpha B/B'-loop-alpha C subregion of Dpl. Fluorescence quenching and equilibrium dialysis analyses of this Dpl(101-145) peptide were compatible with a binding site of Kd = 0.4 µM. Diethylpyrocarbonate footprinting (Qin, K., Yang, Y., Mastrangelo, P., and Westaway, D. (2002) J. Biol. Chem. 277, 1981-1990) of Dpl(27-154) defined one residue/molecule was protected by copper from diethylpyrocarbonate adduct formation, and reiteration of this analysis with Dpl(101-145) suggested that His131 may contribute to Cu(II) binding. Taken together, our data indicate that the alpha -helical region of mouse Dpl possesses a selective copper-binding site with a submicromolar Kd and perhaps one or more lower affinity sites. Although metallated forms of Dpl might exist in vivo, analyses of Tg(Dpl)10329 mice were inconsistent with reports that Dpl expression is associated with increased carbonylation and nitrosylation of brain proteins. Thus, rather than comprising an important source of free radical damage, copper binding may serve to modulate the activity, stability, or localization of the Dpl protein.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The cellular prion protein (PrPC)1 and Doppel (Dpl) are glycosylphosphatidylinositol-anchored proteins with alpha -helical C-terminal domains. Whereas PrPC is expressed in the central nervous system and many peripheral tissues, the most notable site of Dpl expression is the testis (2, 3), although transient expression in endothelial cells of the developing central nervous system has also been described (4). Both proteins can engender neurodegenerative diseases. PrPC serves as a precursor to a malfolded isoform denoted PrPSc in prion infections such as scrapie and is mutated in familial prion diseases such as familial Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker syndrome (5). In the case of Dpl, neuronal expression results in the death of cerebellar cells by apoptosis (6, 7).

Although PrPC was first described in 1985 (8), discerning its physiological function has proven to be challenging (9). The absence of PrP in homozygous null mice was once thought to cause a profound cerebellar ataxia (10), but it is now clear that this syndrome is an artifact of the genetic engineering used to create the deleted PrP gene (Prnp) alleles, resulting in ectopic expression of Dpl (2, 6, 7, 11). Recent analyses have instead focused on a potential role for PrPC in signal transduction (12), interactions with other cell surface proteins (13), and perhaps elements of the extracellular matrix (14-16). Several reports have established that under conditions of oxidative or cellular stress, PrPC can serve a protective role (17-19).

One particularly intriguing connection concerns the ability of PrPC to bind copper ions. Many studies have documented the selectivity, multivalence, and pH dependence of Cu(II) binding, as well as binding constants potentially compatible with Cu(II) occupancy in vivo (20-23). There is a broad consensus that the N-terminal region of PrP is the major contributor to copper binding ability. This glycine-rich domain, absent from Dpl, contains five "octarepeat" motifs. Although the first repeat is of the general form PGGGGWGQ, the four following identical repeats PHGGGWGQ bear histidine residues and bind copper in a cooperative fashion (Hill coefficient, ~3.5) (21, 23, 24). One plausible scenario for physiological activity, based upon stimulation of endocytosis by extracellular copper (25, 26), is that PrPC plays a role in copper uptake or scavenging, perhaps germane to the synaptic location of this molecule. An alternative viewpoint is that PrPC possesses a superoxide dismutase-like enzymatic activity (27). Irrespective of these two contrasting views of the physiological role of PrPC, it is to be emphasized that genetic evidence exists for the importance of the main copper-binding domain, insofar as alterations in the number of octarepeats cause familial prion diseases (28-31).

In addition to the octarepeat Cu(II) binding site of PrPC, there has been interest as to the existence of additional Cu(II)-binding sites C-terminal to these motifs. In the course of our studies to inventory Cu(II)-binding sites in recombinant PrP, we reasoned that Dpl, a PrP-like protein lacking octarepeats, would comprise a useful control. Unexpectedly, as described below, Dpl was found to exhibit selective Cu(II) binding with an affinity comparable with that of PrP.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Dpl Peptide and Proteins-- Mouse Doppel 27-154 (MoDpl(27-154)) refolded by a copper catalysis method (3) and mouse Doppel 26-157 (MoDpl(26-157)) refolded in the presence of glutathione (32) were prepared as described previously. Intrinsic copper content was determined by atomic absorption spectrophotometry. A MoDpl helix-loop-helix peptide was synthesized by standard Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry. This peptide corresponds to residues 101-145 of the mouse doppel and includes the interrupted alpha -helix B (alpha B/B'), the alpha -helix C (alpha C), and the loop between these two helical structures (32). The disulfide bond was introduced by treating the peptide overnight in an aerated solution of ammonium bicarbonate. Protein concentrations were calculated by amino acid hydrolysis (33). Far-UV CD measurements, endoproteolysis, and S-carbamidomethylation of cysteines to determine the presence of integrity of disulfide bonds were carried out as described previously (3, 33).

Fluorescence Spectroscopy and Titrations-- Steady-state fluorescence spectra were recorded on a Photon Technology International QM-1 spectrophotometer. Emission spectra were collected from 310 to 400 nm (lambda ex = 280 nm, 1 s/nm, band pass = 1 nm for excitation and emission). For Cu(II) binding experiments, MoDpl(101-145), MoDpl(27-154) or MoDpl(26-157) were diluted to a final concentration of 0.7 µM in 25 mM N-ethylmorpholine, pH 7.4, 150 mM KCl (NEMO-KCl buffer). The sample volumes were 1 ml, and the experiments were performed at room temperature. The protein was titrated with a concentrated Cu(II) stock such that sample dilution was never more than 1.7%. To detect metal binding selectivity, 1, 2, or 3 µM CuCl2, ZnCl2, NiSO4, MgCl2, CaCl2, or MnCl2 was mixed with 0.7 µM MoDpl(27-154). The emission spectrum was collected after each CuCl2 addition, and fluorescence intensities from 310 to 380 nm were integrated.

Coordination, Modification, and Digestion of MoDpl(101-145) Peptide-- Prior to MALDI-MS analysis, MoDpl helix-loop-helix (90 µM) was incubated with 10-fold molar excess CuCl2, ZnCl2, NiSO4, MgCl2, CaCl2, MnCl2, or FeSO4 in 25 mM NEMO-KCl buffer, pH 7.4, at room temperature for 1 h. Sequencing grade chymotrypsin (Roche Molecular Biochemicals) was used to digest the intact peptide and copper-peptide complex for 2 h at room temperature (the ratio of enzyme:protein was 1:20). In some cases, before chymotrypsin digestion, the samples were incubated with 5-fold molar excess diethlpyrocarbonate (DEPC) at room temperature for 30 min. The samples were then analyzed by using MALDI-MS as described previously (1).

Equilibrium Dialysis-- MoDpl(101-145) and control protein (HuPrP(23-98): (21)) were prepared in NEMO-KCl buffer, pH 7.4. Chelate solution (Gly:Cu:Gly) was prepared by mixing CuSO4 solution with a 2-fold molar excess of glycine and then adjusting the pH to 7.4. The equilibrium dialysis experiments were carried out in multiple 5-cell equilibrium dialyzers (Spectrum Industries). One ml of protein plus chelated Cu(II) mix (retentate) and 1 ml of buffer (dialysate) were placed on opposite sides separated by a 1-kDa cut-off cellulose ester membrane (Spectrum Industries) in a dialysis chamber. For a given experiment, the concentration of protein was held constant, and the concentration of chelated Cu(II) was varied over a Cu(II):protein ratio from 0.5:1 to 40:1. The system was rotated to come to equilibrium for 108 h at 4 °C (verified by analysis of "blank reactions" not containing protein), and the concentration of all forms of copper in each half-chamber was measured by atomic absorption spectroscopy. 2.5 µM protein was used in all of the equilibrium dialysis experiments.

Copper Determinations-- Copper was determined by means of graphite furnace atomic adsorption spectrophotometry. Protein samples for analysis were diluted with 0.5% nitric acid (nitric acid Ultrex II; J. T. Baker) to concentrations within the linear range of graphite furnace copper measurements. The dilution range varied from 10 to 520 times. The diluted samples were transferred to Eppendorf tubes and placed within the autosampler of the atomic adsorption spectrophotometer (Varian Graphite Furnace GTA 100/Varian Spectra 880), and absorbance was measured using furnace conditions developed in the trace element laboratory. Calibration was against working standard solutions prepared by dilution with 0.5% nitric acid from a 1000 mg/liter copper standard (J. T. Baker). Concentrations of stock solutions used for fluorescence quenching studies were verified by atomic absorption spectroscopy.

Mice-- Tg(Dpl) and non-Tg littermate mice (Tg(Dpl) line 10329) have been described previously (7). Mice were between 15 and 20 weeks of age at the time of analysis.

Antibodies-- The anti-Dpl rabbit polyclonal antibody E6977 raised against recombinant mouse doppel (7) was used as described below. The anti-nitrotyrosine antibody was from Cayman Chemical (a gift from N. Cashman), whereas antibodies against 2,4-dinitrophenylhydrazine were obtained from Intergen.

Western Blotting-- 10% (w/v) homogenates of half brains were prepared in 0.32 M sucrose supplemented with one complete-mini protease inhibitor tablet (Roche Diagnostics) on ice. Homogenates were aliquoted and stored at -80 °C until needed. The total protein concentration of each sample was determined using Bradford assay reagents (Bio-Rad) as per the manufacturer's instructions. For the immunoblot analysis of Doppel expression and nitrosylation, samples of 50 µg of total brain protein were prepared and boiled in loading buffer for 9 min and then centrifuged at 20,800 × g for 5 min prior to fractionation by SDS-polyacrylamide gel electrophoresis. The samples were loaded onto a 10-20% Tricine gradient gel (Novex) and electrophoresed at 100 V for ~100 min. The samples were then transferred onto 0.2 µm nitrocellulose (Schleicher & Schuell) for ~80 min at 25 V (Novex semi-dry apparatus). The blots were blocked with 5% (w/v) milk powder in Tris-buffered saline (pH 7.4), 0.02% Tween 20 (Buffer A) for 1 h with gentle agitation at room temperature and then probed with the appropriate primary antibody (anti-Dpl E6977 used 1:4000, anti-nitrotyrosine used 1:5000) in 0.5% milk powder in Tris-buffered saline (pH 7.4), 0.02% Tween 20 overnight at 4 °C. The appropriate horseradish peroxidase-conjugated secondary antibodies were used. The blots were visualized using ECL detection reagents (Amersham Biosciences) and exposed on X-Omat AR film (Eastman Kodak Co.).

Detection of Nitrotyrosine Residues-- A positive control for the nitrosylation blot was made just prior to SDS-PAGE. Peroxynitrite was added to 50 µg of a wild type mouse brain homogenate in sodium phosphate buffer while vortexing to create a final concentration of 15 mM peroxynitrite. After 2 min, 2× gel loading buffer was added to quench the reaction, and the sample was kept on ice. The positive control as well as the sample homogenates of 50 µg of total brain protein were subjected to Western blot analysis with a monoclonal anti-nitrotyrosine primary antibody in Buffer A.

Detection of Reactive Carbonyl Groups-- The amount of carbonyl groups introduced into the total protein of the brain homogenates via oxidative modification was detected using the OxyBlot protein oxidation detection kit (Intergen). Samples of 15 µg of total brain proteins in 0.32 M sucrose and 2% 2-mercaptoethanol were denatured and then derivatized with 2,4-dinitrophenylhydrazine, electrophoresed, and electroblotted as per the manufacturer's instructions. The blots were blocked with 1% (w/v) bovine serum albumin in phosphate-buffered saline (pH 7.4), 0.05% Tween 20 for 1 h at room temperature and then probed with a rabbit anti-DNP primary antibody, used at a concentration of 1:150 in blocking solution overnight at 4 °C. Following incubation with the goat anti-rabbit horseradish peroxidase-conjugated secondary antibody, blots were visualized using ECL or ECL-Plus detection reagents as described above or subjected to protein quantification using ImageQuant software (Molecular Dynamics, Inc.), respectively.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Recombinant Dpl Proteins and a Synthetic Dpl Peptide-- To exclude trivial or idiosyncratic effects pertaining to expression and purification of Dpl proteins from Escherichia coli, we used two recombinant polypeptides prepared by different methods (3, 32) (in the absence of the N-terminal sequences of mature Dpl isolated from mammalian cells, the lengths of these two proteins, Dpl(27-154) versus Dpl(26-157), merely reflect ambiguities in assigning N- and C-terminal signal peptides by different algorithms). For Dpl(27-154) prepared by oxidative refolding in catalytic concentrations of Cu(II), we used atomic adsorption spectroscopy to quantify residual metal content (<3 × 10-4 mol of copper/mol of dialyzed protein). Extrapolating from studies attributing special significance to the helix B/B'-loop-helix C region of Dpl (34), we hypothesized that this area of Dpl may comprise a site with biological activity and synthesized a corresponding peptide, Dpl(101-145) (Fig. 1A). This peptide encompasses one of the two disulfide bonds present in full-length Dpl, the "inner" Cys109-Cys143 linkage located at an equivalent position to the single disulfide bond present in PrP. Measured in NEMO-KCl buffer at pH 7.4, Dpl(101-145) exhibited a CD spectrum with minima at 208 and 222 nm, indicative of a high alpha -helical content (Fig. 1B). MALDI-MS analysis of Dpl(101-145) peptide showed a single charged peptide signal at m/z 5162.9 (Fig. 2A), in excellent agreement with the calculated molecular mass of 5162.9 Da as [M+H]+. S-Carbamidomethylation (3, 33) was used to verify the presence of appropriate disulfide linkages in the recombinant polypeptides (not shown) and Dpl(101-145) peptide (see Fig. 6A) used for the following analyses.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   Properties of the Dpl(101-145) peptide. A, schematic showing predicted chymotrypsin cleavage sites and the disulfide linkage. B, CD spectrum of the Dpl(101-145) peptide (48 µM) in 25 mM N-ethylmorpholine, 30 mM KCl (NEMO-KCl) buffer, pH 7.4, measured at room temperature. The spectrum indicates a high alpha -helical content.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2.   MALDI-MS analysis of metal binding to MoDpl(101-145). A-H, spectra obtained with or without the indicated divalent cations, as described under "Materials and Methods."

MALDI-MS Analysis of Dpl(101-145)-- Because MALDI-MS provided some of the first evidence in favor of copper binding by PrP (20), this technique was applied to Dpl(101-145). After incubation with 10× molar excess of CuCl2 in NEMO-KCl buffer, pH 7.4, at room temperature for 1 h, Cu(II)-peptide complexes were detected. In addition to intact protein at m/z 5162.9, additional peaks at m/z 5225.4 and 5286.7 were observed in the presence of copper (Fig. 2B). Averaged over three experiments, the starting material and derivatives were established as 5162.63 ± 1.42, 5225.90 ± 0.78, and 5287.23 ± 1.09 Da, yielding individual mass increments of 63.3 and 61.3 Da, respectively, and an averaged figure of 62.3 Da. These data are consistent with up to 2 mol of copper (mass 63.5 Da) added per mole of peptide under the conditions of this assay, although intrinsic errors for the mass determinations do not permit conclusions as to how many protons are expelled from the protein commensurate with copper binding. To detect whether other divalent ions bound to Dpl, MoDpl(101-145) was incubated with 10× molar excess of Zn(II), Ni(II), Mg(II), Ca(II), Mn(II), or Fe(II) in NEMO-KCl buffer, pH 7.4, at room temperature for 1 h prior to MALDI-MS analysis. However, in agreement with fluorescence quenching studies presented in Fig. 3, no signals corresponding to metal-peptide complexes were detected in these other analyses (Fig. 2, C-H).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of Cu(II) on Dpl proteins and Dpl(101-145) peptide measured by fluorescence spectrometry. Fluorescence quenching by addition of copper was determined for Dpl(27-154) (A and B), Dpl(26-157) (C and D), and MoDpl(101-145) peptide (E and F). A, C, and E, fluorescence emission spectra at different Cu(II) concentrations using protein at 0.7 µM. B, D, and F, the change in fluorescence intensity integrated over a wavelength range of 310-380 nm plotted against copper concentration (abscissa); thus, 1.0 on the ordinate indicates 100% (maximal) observed fluorescent change. The binding curves represent the best fits of Equations 1 and 2 (main text) to the data with the polypeptide concentrations set at the measured values of 0.7 µM. The data were also fitted with the concentration of polypeptide fixed at 1.4 µM (i.e. the total concentration of two binding sites) for comparison of residuals and chi-squared values (curves not shown: see main text). The residual plots (lower panels of B, D, and F) indicate deviations between data points and the model with the polypeptide concentration set at 0.7 µM (filled circles, 1:1 binding model) or 1.4 µM (open circles, 2:1 binding model). The chi-squared values, whose magnitudes are inversely proportional to the closeness of model and the data points, are: Dpl(26-154), 1:1 binding, 0.028; 2:1 binding, 0.078; Dpl(27-157), 1:1 binding, 0.014; 2:1 binding, 0.058; Dpl(101-145), 1:1 binding, 0.006; and 2:1 binding, 0.022. G, the fluorescence intensity change integrated over the wavelength range of 310-380 nm of 0.7 µM Dpl(27-154) in 3 µM of various metal ions.

Copper-Protein Interactions Assessed by Fluorescence Quenching-- Fluorescence quenching analysis for recombinant mouse Doppel (recDpl) was undertaken exploiting the intrinsic properties of four tryptophan residues at positions 35, 85, 136, and 151, and five tyrosine residues at positions 78, 79, 84, 91, and 92 (present within both Dpl(27-154) and Dpl(26-157)). To confirm that these residues undergo a change in environment, we measured the change of fluorescence intensity of Trp and Tyr residues upon Cu(II) addition. The diminutions in intrinsic fluorescence (integrated from 310 to 380 nm) induced by Cu(II) addition were 26% for Dpl(27-154) and 30% for Dpl(26-157). However, the change in the intensity was not accompanied by a significant shift in the wavelength position of the maximum (lambda max), suggesting that the solvent accessibility of Trp residues are not affected significantly by copper binding. Also, CD spectra were not notably altered by copper addition (not shown), suggesting that copper binding is not accompanied by a significant change in the secondary structure of recDpl. MoDpl(101-145) contains a single tryptophan residue at position 136 (Fig. 1A), facilitating similar fluorescence spectroscopic studies to those performed for the aforementioned full-length recDpl molecules.

Binding affinities and stoichiometries for copper binding to the various proteins and peptides were quantified by fitting of the conventional model expressed in Equations 1 and 2 to the fluorescence data in Fig. 3,
F=F<SUB>0</SUB>+&Dgr;F [<UP>bound</UP>]<UP>/</UP>[<UP>P</UP>] (Eq. 1)
where F is the measured fluorescence, normalized by taking the difference in the first and last data point as 1, F0 is the fitted fluorescence before addition of copper, and Delta F is the fitted change in fluorescence. The concentration of the Dpl-copper complex, [bound] is described in Equation 2,
[<UP>bound</UP>]={K<SUB>d</SUB>+[<UP>Cu</UP>]<SUB><UP>tot</UP></SUB> (Eq. 2)

+[<UP>P</UP>]−sqrt[(K<SUB>d</SUB>+[<UP>Cu</UP>]<SUB><UP>tot</UP></SUB>−[<UP>P</UP>])<SUP>2</SUP>−4[<UP>Cu</UP>]<SUB><UP>tot</UP></SUB>[<UP>P</UP>]]}<UP>/2</UP>
where Kd is the dissociation constant of the copper-binding site(s), [Cu]tot is total copper concentration, and [P] is protein concentration. In accord with data presented in Figs. 2 and 5, binding was considered in terms of "one-site" and "two-site" models. The protein concentration terms in Equations 1 and 2 were first set to the measured value of 0.7 µM (i.e. one copper-binding site/molecule), and the best fits of the model to the data are shown in the lower panels of Fig. 3 (B, D, and F). The affinities of Dpl(27-154) and Dpl(27-157) for copper were essentially identical. For Dpl(27-154), a unique binding site would have a Kd value of 0.16 ± 0.08 µM (Fig. 3B), and for Dpl(26-157), the analogous value is Kd = 0.20 ± 0.05 µM (Fig. 3D). Remarkably, copper was found to interact with the 44-mer, Dpl(101-145) with nearly the same characteristics as seen for the larger fragments; for a unique site, the Kd for a copper-peptide complex is estimated to be 0.36 ± 0.04 µM (Fig. 3F).

Residual plots and chi-squared values for the best fits to the data of Equation 1 were also ascertained for when [P] was set at 1.4 µM, which would hold if two copper ions bound to two similar sites in one protein or peptide molecule. Smaller deviations between model and data for the 1:1 model than for the 2:1 model were apparent in the residual plots (Fig. 3, B, D, and F, lower panels). Chi-squared values, which increase with differences between the model and data, were smaller in all cases for the 1:1 binding model than for the 2:1 model (Fig. 3, legend). Modeling the stoichiometry at levels of 3:1 and beyond by increasing [P] during fitting led to progressively poorer agreement with the data (not shown). Taken together, these results do not support the hypothesis of two similar copper sites/polypeptide, in agreement with the absence of palindromic or repeated amino acid sequences in Dpl. These data are compatible with an interpretation that each mole of protein binds 1 mole of copper at a single predominant site under the particular conditions of the assay. However, the presence of a weaker binding site or of a second binding site associated with a metal-peptide complex with different fluorescent properties cannot be excluded based solely upon these fluorescence titrations.

To evaluate metal binding selectivity of the Dpl protein, we calculated the fluorescence intensity change of 0.7 µM Dpl(27-154) in the presence of 3 µM divalent cations, e.g. Cu(II), Zn(II), Ni(II), Mg(II), Ca(II), and Mn(II). Whereas no significant changes of Trp and Tyr fluorescence signals were observed for other cations (1.18 ± 0.40% for Zn(II), 2.85 ± 0.40% for Ni(II), 2.60 ± 0.20% for Mg(II), 2.60 ± 0.18% for Ca(II), and 1.91 ± 0.10% for Mn(II)) (Fig. 3G), Cu(II) induced a 25.85 ± 0.39% quench of fluorescence intensity (Fig. 3G, first column). Although we cannot exclude that Dpl complexes (which do not result in fluorescent changes) with metals other than copper exist, we note that similar selectivity was found in MALDI-MS analyses (Fig. 2). Also, these data are strikingly reminiscent of prior studies of selective interactions between copper and hamster PrP (22).

Copper Binding to Dpl(101-145) Assessed by Equilibrium Dialysis-- In the equilibrium dialysis experiments, Cu(II) was presented to 2.5 µM MoDpl(101-145) as a glycine chelate. Binding data are shown in Fig. 4. Graphing [bound] versus [Cu]tot yielded a plateau at about 2.5 µM, the same concentration as the protein used in the experiments. Fitting Equation 2 to the data gives Kd = 0.4 ± 0.2 µM, the same within experimental error as that determined by fluorescence titration, and [protein] = 2.49 ± 0.13 µM, very similar to the concentration of the protein used in the experiment, indicating a 1:1 correspondence between protein monomers and copper-binding sites. Equilibrium dialysis therefore confirms both that there is one copper-binding site/monomer and that fluorescence provides a reliable signal for the rapid measurement of copper binding to Dpl.


View larger version (8K):
[in this window]
[in a new window]
 
Fig. 4.   Copper binding to Dpl (101-145) peptide assessed by equilibrium dialysis. A plot of the concentration of the MoDpl-copper complex ([bound]) versus the total concentration ([Cu]tot), where and [bound] = [Cu]retentate - [Cu]dialysate. Copper was presented to peptide in the form of a copper:glycine2 chelate, and the peptide concentrations were 2.5 µM throughout. The solid line represents the best of Equation 2 to the data with Kd = 0.4 ± 0.2 µM and [protein] = 2.49 ± 0.13 µM.

DEPC Footprinting of Dpl(27-154)-- In a further technique to interrogate copper binding by Dpl(27-154), we exploited the ability of copper to protect certain reactive amino acid residues (predominantly histidine) from chemical modification with DEPC (1). Upon incubation of native protein (15 µM) (Fig. 5A) with DEPC, up to nine DEPC adducts were detected per mole of Dpl(27-154) (Fig. 5B), assuming an increment of 72.06 Da/mono-carbethoxylated adduct. In the case of protein preincubated with a molar excess of copper, there was a shift of n - 1 in the spectrum of adducts (Fig. 5C), indicating that one DEPC-reactive residue was protected from modification by the presence of copper.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 5.   DEPC footprinting of native Dpl(27-154). A, unreacted protein. B, mass spectrum of DEPC-modified Dpl(27-154) protein. C, mass spectrum of DEPC-modified protein preincubated with Cu(II).

Copper Binding in the Region of Dpl(122-136)-- Chymotrypsin digestion was used to map the location of Cu(II)-binding site(s) detected by the prior MALDI-MS analysis of Dpl(101-145). In the absence of Cu(II) (Fig. 6A), a prominent peak at m/z 1910.05 correspond to a partially digested chymotryptic peptide containing amino acid sequences 122-136 (C3 + C4 + C5 + C6, calculated 1910.03 Da). An additional peak at m/z 1032.70 corresponds to 137-145 (C7 + C8, calculated 1032.58 Da; not shown), whereas the peak at 3286.31 corresponds to disulfide-linked (101-121)-S-S-(137-145) dipeptide. In the presence of Cu(II), two new peaks were observed at m/z 1973.50 and 2036.07 Da, indicating that up to two copper ions can bind to the area between amino acids 122 and 136. This chymotryptic peptide has the sequence SREKQDSKLHQRVLW. Mass increments upon addition of the first and second Cu(II) ions were 62.69 and 62.57 Da, respectively (Fig. 6B), yielding a net increment of 125.26 Da, in close agreement with the figure of 124.60 Da obtained for intact Dpl(101-145) peptide.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 6.   Copper binding and DEPC footprinting of Dpl(101-145)-derived chymotryptic peptides. A, chymotryptic peptides. B, chymotryptic peptides observed with samples subsequent to preincubation with Cu(II). Note the "additional" peaks adjacent to the peak at m/z 1910.81, compatible with one or two copper adducts (1Cu and 2Cu, respectively) and invariance of the disulfide cross-linked chymotryptic fragments. C, chymotryptic digest of DEPC-reacted peptide. The prominent peak at m/z 1910.08 in A and B is diminished in amplitude, and two new peaks of mono-carbethoxylated peptide (1m and 2m) are apparent at m/z 1982.09 and 2055.08. D, Cu(II)-protected DEPC reacted peptide analyzed with chymotrypsin. The intensity of the 1m peak is diminished concomitant with the reappearance of the 122-136 peptide fragment and 1- and 2-Cu-derived complexes.

Histidine-dependent Copper Binding in Dpl(101-145)-- DEPC footprinting was also used to assess the histidine-dependent copper coordination within the Dpl(101-145) peptide. Dpl(101-145) (90 µM) in NEMO-KCl buffer, pH 7.4, was incubated with 5-fold excess DEPC and then digested with chymotrypsin. Compared with the signal in Fig. 6A, the signal at m/z 1910.09 corresponding to unmodified residues 122-136 (C3 + C4 + C5 + C6, calculated 1910.03 Da) was reduced in amplitude (Fig. 6C). Two new peaks were found at m/z 1982.09 and 2055.08 and indicated one mono- and two mono-carbethoxylations of fragment 122-136 (calculated 1982.09 and 2054.14 Da, respectively). A different mass spectrum was obtained when Dpl(101-145) peptide was preincubated with 10-fold excess Cu(II) prior to reaction with DEPC (Fig. 6D). Here the major peaks were at m/z 1910.34, 1973.28, 2036.21, 1982.38, and 2046.31. Diminution of the mono-carbethoxylated peak at 1982.09 and an increase in the peak corresponding to unmodified 122-136 C1 + C2 + C3 peptide (compare with Fig. 6D) indicated that a site of potential DEPC modification was blocked by copper binding. As per Fig. 6B, peaks at m/z 1972.53 and 2036.03 are indicative of the 122-136 peptide with one or two bound copper ions. Additionally, a peak at 2046.31 is likely equivalent to one copper plus one mono-carbethoxylation (calculated 2045.59 Da) (Fig. 6D). These data can be reconciled with hypotheses that (i) a second copper-binding site within Dpl(101-145) is independent of the His131 residue or (ii) binding of a second copper ion involves the second nitrogen in the imidazole ring, with this nitrogen being unmodified in the mono-carbethoxylated adduct. Also, in contrast to Fig. 6B, instead of a peak at m/z 3286.84 Da corresponding to fragment (101-121)-S-S-(137-145), a new peak at m/z 3358.53 Da corresponding to one mono-carbethoxylation (calculated 3358.71) indicates one DEPC modification within this disulfide-bridged fragment (Fig. 6C). No change was observed in this peak (3358.83 Da) in copper and DEPC-treated versus DEPC-treated samples (Fig. 6D), indicating that Cu(II) did not interact with this fragment.

Fine Mapping DEPC Modification of His131 within Dpl(122-136)-- The post-source decay technique of tandem analysis was used to verify DEPC modification and copper protection of His131. Partial post-source decay spectra of fragment 122-136 and its counterpart in DEPC- and copper-DEPC-treated samples are presented in Fig. 7. Fig. 7A shows the scheme of nomenclature for peptide post-source decay fragment ions of chymotryptic peptide 122-136 derived from intact Dpl(101-145). In unmodified samples, a peak at m/z 109.9 corresponds to an immonium histidine ion (His131) (calculated 110.0 Da) (Fig. 7B). After DEPC treatment, a new peak at m/z 181.7 indicated one mono-carbethoxylation of histidine (calculated 182.0 Da) (Fig. 7C). Incubation of the sample with Cu(II) prior to DEPC treatment resulted in the disappearance of one mono-carbethoxylation of histidine and indicates that Cu(II) coordination to this histidine protected the imidazole ring from DEPC modification (Fig. 7D). It is also of note that peaks at m/z 128.7, corresponding to an immonium arginine ion (Arg123 or Arg133) (calculated 129.1 Da), and at m/z 226.9, corresponding to a b2-NH3 ion (SR-NH3, calculated 227.1 Da) were always present (Fig. 7, B-D), indicating that neither fragment ion reacted with DEPC or Cu(II). Another peak for the y9 SKLHQRVLW ion at m/z 1166.7 (calculated 1166.7 Da) in the unmodified sample (Fig. 7B) was replaced by a signal at m/z 1239.6, corresponding to one mono-carbethoxylation of the peptide ion (calculated 1238.8 Da) in the DEPC-treated sample (Fig. 7C). Incubation of the sample with Cu(II) before DEPC treatment led to the disappearance of the mono-carbethoxylation signal and replacement by a signal at 1230.9 (calculated 1230.2 Da), indicating the binding of one copper ion. In sum, the results demonstrate that Cu(II) coordination to a y9 ion protected the peptide ion from DEPC modification and, in turn, the involvement of His131 in coordinating copper ions in the context of the peptide. Given the similarities between the peptide and protein in terms of their sequences, copper affinities, and fluorescence changes in response to copper binding, these results suggest that His131 will coordinate copper in the context of the full-length protein as well.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 7.   Mapping of DEPC modification and Cu(II)-binding site in Dpl by post-source decay analysis. A, scheme of nomenclature of chymotryptic peptide Dpl(122-136) for post-source decay peptide fragment ions. B-D, tandem post-source decay mass spectra of chymotryptic peptide Dpl(122-136) (B), chymotryptic carbethoxylated peptide Dpl(122-136) (C), and chymotryptic carbethoxylated copper-peptide Dpl(122-136) complex (D). m, monocarbethoxylation.

Dpl Expression and Oxidative Damage-- The proposal that Dpl expressed in the central nervous system is a source of oxidative damage (35) has a potential parallel in the notion that Dpl is metallated in vivo and thus may be a source of free radicals. Prior analyses in this area examined the Dpl-expressing Rcm0 line of Prnp0/0 mice (35). To address Dpl as a source of oxidative damage in vivo, we exploited Tg(Dpl) mice created with the hamster PrP gene promoter, exhibiting potent central nervous system expression of Dpl and ataxia at about 1 year of age (7). Brain homogenates of non-Tg and Tg(Dpl)10329 mice were subjected to polyacrylamide gel electrophoresis and probed with antibodies to known markers of oxidative stress. As seen in Fig. 8A, Tg(Dpl) mice express Dpl in the central nervous system, as demonstrated by the strong heterodisperse signals at ~34 kDa, when compared with non-Tg controls. When samples of the same homogenates were analyzed for nitrotyrosine modification of proteins using an anti-nitrotyrosine antibody, low signal intensities were obtained, and no obvious differences in the levels of nitrotyrosine formation between Tg(Dpl) and non-Tg mice (Fig. 8B) were found. Furthermore, modification of carbonyl groups, another direct indication of oxidative stress, also appeared to be unrelated to increased doppel expression (Fig. 8C). Quantification of this blot for reactive carbonyl groups is presented in Fig. 8D, revealing no significant differences between the Tg(Dpl) and non-Tg sample groups (p = 0.97).


View larger version (61K):
[in this window]
[in a new window]
 
Fig. 8.   Protein nitrosylation and carbonylation in Tg(Dpl) mice. A, analysis with Dpl antibody. Non-Tg Dpl (lanes 1 and 2) and Tg(Dpl) (lanes 3 and 4) mouse brain homogenates immunoblotted with the anti-Dpl E6977 antibody demonstrate the relative levels of Dpl expression in the samples used. Cross-reactive bands between 78 and 210 kDa present in all samples served to demonstrate uniform sample loading. B, analysis of nitrotyrosinylation. Lane 1, peroxynitrate-treated wild type positive control (+Ctl) brain homogenate. Non-Tg (lanes 2 and 3) and Tg(Dpl) (lanes 4 and 5) brain homogenates were probed with an anti-nitrotyrosine antibody. These analyses demonstrated similar, very low levels of immunoreactivity (indicative of nitrotyrosine modification) in non-Tg and Tg(Dpl) mice. C, analysis of protein carbonyl groups. 15-µg samples of non-Tg (lanes 1 and 2) and Tg(Dpl) (lanes 3 and 4) total brain protein was derivatized with 2,4-dinitrophenyhadrazine and immunoblotted to detect relative levels of reactive carbonyl groups. Underivatized control samples yielded no signal (not shown). D, quantitative representation of carbonyl immunoreactivity via phosphorimaging analysis. A paired t test yielded a p value of 0.97. There is no significant difference between the non-Tg and Tg samples.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Metal Binding to Dpl in Vitro-- Many studies have documented binding of one copper ion/histidine containing octarepeat within PrP, when measured at neutral pH (Ref. 36 and references therein). In addition to these four sites, there is growing agreement upon the existence of a fifth copper site within PrP located slightly C-terminal to the octarepeats and likely involving histidines 95 and 111 (mouse PrP numbering scheme) (1, 37-39). Although sequence alignments reveal that none of these residues have an equivalent in Dpl, our in vitro studies have revealed, nonetheless, that Dpl also possesses copper binding properties.

It is unlikely that the copper binding detected in our studies has a trivial origin. Although contaminants from E. coli capable of binding copper can be hypothesized, they would have to be present in substantial quantities to account for the observed stoichiometry of >= 1 mol of copper/mol of polypeptide. We also note that similar fluorescence quenching properties were produced by two forms of recDpl prepared by different chromatographic procedures. Furthermore, a Dpl(101-145) peptide synthesized in vitro also had the ability to bind copper (Fig. 2), as did a Dpl(122-136) proteolytic derivative of this peptide (Fig. 6). Another notable feature of the interaction with copper is the degree of specificity. Assessed by fluorescence quenching, the Dpl substrates exhibited no discernable affinity for other divalent cations, a pattern of selectivity reminiscent of PrP itself (1, 20, 22). Although it is possible that peptide complexes formed by metals other than copper have fluorescent properties similar to that of Dpl apo-protein and thus appear not to interact in this assay, the similar pattern of metal specificity derived from MALDI-MS analysis (Fig. 2) tends to argue against this interpretation and in favor of an intrinsic metal selectivity.

Our experiments demonstrate that Cu(II) binding to recDpl can be largely attributed the alpha B/B'-loop-alpha C domain; using fluorescence quenching, Kd values for full-length protein and Dpl(101-145) differ only by a factor of two. Binding assessed directly by equilibrium dialysis and indirectly by fluorescence quenching analysis can be accounted for by a single-site model, with the additional site detected by MALDI-MS analysis, perhaps reflecting contribution of a low affinity site only filled by high concentrations of Cu(II). In the NMR structure for Dpl (32), the alpha B/B'-loop-alpha C domain lies at the opposite end of the molecule from the free C terminus (the site of the glycosylphosphatidylinositol anchor addition) and may therefore be displayed toward the extracellular environment in vivo. The notion of copper-binding sites within the alpha -helical domain of a cellular prion protein has a precedent from studies of PrP (40). Of potentially greater importance, this region of the Dpl molecule encompassing a kinked helix B (alpha B/B') contributes to a triangular hydrophobic pocket with no exact equivalent in PrP (32). It will be of interest to determine the details of how amino acid residues in this vicinity contribute to copper binding. The observation that a cluster of fCJD mutations in the helix B-loop-helix C region of PrP recapitulate conserved residues in Dpl provides further impetus for deciphering the biological properties of this region of the protein (34).

Regarding the issue of binding affinity, some of our analyses use copper in the form of CuCl2. Such solutions contain oxy and hydroxy polymers of copper, which may be kinetically inert (41). Accordingly, some studies of PrP have instead used copper presented in the form of glycine- or histidine-chelated complexes. These experiments still yield binding at micromolar concentrations of copper, but back-calculations based upon the dissociation constants of the metal-amino acid complexes can be used to derive a concentration for free ionic metal and protein-metal binding constants estimated in the range of 10-14 M (38). Our equilibrium dialysis binding analysis of Dpl(101-145) was performed with glycine-chelated copper and a Kd value for a high affinity site of 0.4 ± 0.2 µM. Irrespective of the validity of back-calculating ionic copper concentrations from experiments using copper chelates (where ternary complexes of protein/copper/amino acid complexes might also have to be considered (42)), our numerical data (i) are nonetheless quite similar to estimates of binding constants derived from "uncorrected" binding data for PrP obtained under similar conditions (21) and (ii) illustrate that Dpl, like PrP, can extract copper from an amino acid chelate, a form that might better approximate presentation in biological fluids than in solutions of copper salts. "Exchangeable" copper in plasma bound to amino acids has been estimated at 3.6 µM, whereas the total copper levels in plasma and seminal fluid are measured at 15.5 ± 9 and 5.9 ± 3.7 µM, respectively (43, 44) and are thus about 1 order of magnitude above the Kd values presented herein. These data strongly suggest that metallated forms of Dpl could exist in vivo, which is of potential relevance to physiological function(s) in spermatogenesis and also to the pathological effect of central nervous system expression.

Central Nervous System Expression of Dpl: Oxidative Damage and Neurotoxicity-- Based upon prior connections between copper-polypeptide complexes and the generation of reactive free radical species, we investigated indicators of oxidative damage in Tg(Dpl) mice (35). Ectopic expression of Dpl in the brain is known to be toxic, and genetically engineered mice with this property succumb to an ataxic syndrome characterized by apoptotic death of cerebellar cells (2, 6, 7). Our studies exploited the Tg(Dpl)10329 line of mice (7). In contrast to another study (35), we found no evidence of enhanced oxidative damage to brain proteins (Fig. 8). This discrepancy cannot be attributed to the penetrance of the disease phenotype in the Tg(Dpl)10329 mice studied here. Tg(Dpl)10329 mice develop an ataxic syndrome at 375 ± 8 days, as compared with Rcm0 mice, which develop ataxia much later in life at 611 ± 12 days of age. Furthermore, the Tg(Dpl)10329 mice at age of sacrifice in the analyses of oxidative markers described here were approximately twice as old as Rcm0 mice analyzed for markers of oxidative damage (35). It is possible that the discrepancy between our findings and those of Wong et al. (35) reflects a contribution of modifier loci deriving from different genetic backgrounds. Nonetheless, because the Tg(Dpl)10329 mice described here have levels of protein carbonyl and nitrotyrosine formation no different from those seen in non-Tg mice (yet are certainly prone to loss of cerebellar cells), it seems quite unlikely that the neurotoxic properties of Dpl depend upon causing oxidative damage to proteins.

Competition between Dpl and PrPC: a Role for Cu?-- Despite our failure to implicate oxidative damage in the neurotoxic action of Dpl, it remains plausible that an ability to bind copper ions is necessary for neurotoxicity proceeding by a different, but as yet undefined, mechanism. The studies presented here were not designed to elucidate what this mechanism might be. Nonetheless, by revealing that the ability to bind copper is a property of both Dpl and PrPC, they may speak to "competition" between the PrPC and Dpl proteins in modulating this pathologic process (7). Specifically, because expression of PrPC can nullify the neurotoxicity of Dpl to cerebellar cells, the question now arises as to whether the competing actions of these two glycosylphosphatidylinositol-linked proteins somehow derive from a shared predilection for this particular transition metal. Experiments to recapitulate Dpl-mediated neurotoxicity in a tractable system may allow us to appraise this possibility.

    ACKNOWLEDGEMENTS

We thank Huaping Mo and Jane Dyson for a gift of Dpl(26-157) protein.

    FOOTNOTES

* This work was supported by Canadian Institutes of Health Research Grants MOP363377, MME54190, and MSC46763 and by the Alzheimer Society of Ontario and the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¶¶ To whom correspondence should be addressed: CRND, Tanz Neuroscience Bldg., 6 Queen's Park Crescent West, Toronto, ON M5S 3H2, Canada. Tel.: 416-978-1556; Fax: 416-978-1978; E-mail: david.westaway@utoronto.ca.

Published, JBC Papers in Press, December 13, 2002, DOI 10.1074/jbc.M210875200

    ABBREVIATIONS

The abbreviations used are: PrPC cellular prion protein, MALDI, matrix-assisted laser desorption ionization; MS, mass spectrometry; DEPC, diethylpyrocarbonate; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Qin, K., Yang, Y., Mastrangelo, P., and Westaway, D. (2002) J. Biol. Chem. 277, 1981-1990[Abstract/Free Full Text]
2. Moore, R., Lee, I., Silverman, G. S., Harrison, P., Strome, R., Heinrich, C., Karunaratne, A., Pasternak, S. H., Chishti, M. A., Liang, Y., Mastrangelo, P., Wang, K., Smit, A. F. A., Katamine, S., Carlson, G. A., Cohen, F. E., Prusiner, S. B., Melton, D. W., Tremblay, P., Hood, L. E., and Westaway, D. (1999) J. Mol. Biol. 293, 797-817
3. Silverman, G. L., Qin, K., Moore, R. C., Yang, Y., Mastrangelo, P., Tremblay, P., Prusiner, S. B., Cohen, F. E., and Westaway, D. (2000) J. Biol. Chem. 275, 26834-26841[Abstract/Free Full Text]
4. Li, A., Sakaguchi, S., Shigematsu, K., Atarashi, R., Roy, B. C., Nakaoke, R., Arima, K., Okimura, N., Kopacek, J., and Katamine, S. (2000) Am. J. Pathol. 157, 1447-1452[Abstract/Free Full Text]
5. Prusiner, S. B., and Scott, M. R. (1997) Annu. Rev. Genet. 31, 139-175[CrossRef][Medline] [Order article via Infotrieve]
6. Rossi, D., Cozzio, A., Flechsig, E., Klein, M. A., Rulicke, T., Aguzzi, A., and Weissmann, C. (2001) EMBO J. 20, 694-702[Abstract/Free Full Text]
7. Moore, R., Mastrangelo, P., Bouzamondo, E., Heinrich, C., Legname, G., Prusiner, S. B., Hood, L., Westaway, D., DeArmond, S., and Tremblay, P. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 15288-15293[Abstract/Free Full Text]
8. Oesch, B., Westaway, D., Wälchli, M., McKinley, M. P., Kent, S. B. H., Aebersold, R., Barry, R. A., Tempst, P., Teplow, D. B., Hood, L. E., Prusiner, S. B., and Weissmann, C. (1985) Cell 40, 735-746[Medline] [Order article via Infotrieve]
9. Mastrangelo, P., and Westaway, D. (2001) Gene (Amst.) 275, 1-18[CrossRef][Medline] [Order article via Infotrieve]
10. Sakaguchi, S., Katamine, S., Nishida, N., Moriuchi, R., Shigematsu, K., Sugimoto, T., Nakatani, A., Kataoka, Y., Houtani, T., Shirabe, S., Okada, H., Hasegawa, S., Miyamoto, T., and Noda, T. (1996) Nature 380, 528-531[CrossRef][Medline] [Order article via Infotrieve]
11. Weissmann, C., and Aguzzi, A. (1999) Science 286, 914-915[Free Full Text]
12. Mouillet-Richard, S., Ermonval, M., Chebassier, C., Laplanche, J. L., Lehmann, S., Launay, J. M., and Kellermann, O. (2000) Science 289, 1925-1928[Abstract/Free Full Text]
13. Schmitt-Ulms, G., Legname, G., Baldwin, M. A., Ball, H. L., Bradon, N., Bosque, P. J., Crossin, K. L., Edelman, G. M., DeArmond, S. J., Cohen, F. E., and Prusiner, S. B. (2001) J. Mol. Biol. 314, 1209-1225[CrossRef][Medline] [Order article via Infotrieve]
14. Brimacombe, D. B., Bennett, A. D., Wusteman, F. S., Gill, A. C., Dann, J. C., and Bostock, C. J. (1999) Biochem. J. 342, 605-613[CrossRef][Medline] [Order article via Infotrieve]
15. Hundt, C., Peyrin, J. M., Haik, S., Gauczynski, S., Leucht, C., Rieger, R., Riley, M. L., Deslys, J. P., Dormont, D., Lasmezas, C. I., and Weiss, S. (2001) EMBO J. 20, 5876-5886[Abstract/Free Full Text]
16. Gonzalez-Iglesias, R., Pajares, M. A., Ocal, C., Espinosa, J. C., Oesch, B., and Gasset, M. (2002) J. Mol. Biol. 319, 527-540[CrossRef][Medline] [Order article via Infotrieve]
17. Brown, D. R., Schulz-Schaeffer, B., Schmidt, B., and Kretzschmar, H. A. (1997) Exp. Neurol. 146, 104-112[CrossRef][Medline] [Order article via Infotrieve]
18. White, A. R., Collins, S. J., Maher, F., Jobling, M. F., Stewart, L. R., Thyer, J. M., Beyreuther, K., Masters, C. L., and Cappai, R. (1999) Am. J. Pathol. 155, 1723-1730[Abstract/Free Full Text]
19. Bounhar, Y., Zhang, Y., Goodyer, C. G., and LeBlanc, A. (2001) J. Biol. Chem. 276, 39145-39149[Abstract/Free Full Text]
20. Hornshaw, M. P., McDermott, J. R., and Candy, J. M. (1995) Biochem. Biophys. Res. Commun. 207, 621-629[CrossRef][Medline] [Order article via Infotrieve]
21. Brown, D. R., Qin, K., Herms, J., Madlung, A., von Bohlen, A., Manson, J., Strome, R., Fraser, P. E., Kruck, T., Schulz-Schaeffer, W., Giese, A., Westaway, D., and Kretzschmar, H. A. (1997) Nature 390, 684-687[CrossRef][Medline] [Order article via Infotrieve]
22. Stöckel, J., Safar, J., Wallace, A. C., Cohen, F. E., and Prusiner, S. B. (1998) Biochemistry 37, 7185-7193[CrossRef][Medline] [Order article via Infotrieve]
23. Viles, J. H., Cohen, F. E., Prusiner, S. B., Goodin, D. B., Wright, P. E., and Dyson, H. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2042-2047[Abstract/Free Full Text]
24. Whittal, R. M., Ball, H. L., Cohen, F. E., Burlingame, A. L., Prusiner, S. B., and Baldwin, M. A. (2000) Protein Sci. 9, 332-343[Abstract]
25. Pauly, P. C., and Harris, D. A. (1998) J. Biol. Chem. 273, 33107-33110[Abstract/Free Full Text]
26. Sumudhu, W., Perera, W. S., and Hooper, N. M. (2001) Curr. Biol. 11, 519-523[CrossRef][Medline] [Order article via Infotrieve]
27. Brown, D. R., Wong, B. S., Hafiz, F., Clive, C., Haswell, S. J., and Jones, I. M. (1999) Biochem. J. 344, 1-5[CrossRef][Medline] [Order article via Infotrieve]
28. Goldfarb, L. G., Brown, P., McCombie, W. R., Goldgaber, D., Swergold, G. D., Willis, P. R., Cerenakova, L., Baron, H., Gibbs, C. J., and Gajdusek, D. C. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10926-10930[Abstract]
29. Collinge, J., Brown, J., Hardy, J., Mullan, M., Rossor, M. N., Baker, H., Crow, T. J., Lofthouse, R., Poulter, M., Ridley, R., Owen, F., Bennett, C., Dunn, G., Harding, A. E., Quinn, N., Doshi, B., Roberts, G. W., Honavar, M., Janota, I., and Lantos, P. L. (1992) Brain 115, 687-710[Abstract]
30. Beck, J. A., Mead, S., Campbell, T. A., Dickinson, A., Wientjens, D. P., Croes, E. A., Van Duijn, C. M., and Collinge, J. (2001) Neurology 57, 354-356[Abstract/Free Full Text]
31. Capellari, S., Parchi, P., Campbell, J., Posey, D. M., Petersen, R. B., and Gambetti, P. (2002) Neurology 59, 1628-1630[Abstract/Free Full Text]
32. Mo, H., Moore, R. C., Cohen, F. E., Westaway, D., Prusiner, S. B., Wright, P. E., and Dyson, H. J. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 2352-2357[Abstract/Free Full Text]
33. Qin, K., Yang, D. S., Yang, Y., Chishti, M. A., Meng, L. J., Kretzschmar, H. A., Yip, C. M., Fraser, P. E., and Westaway, D. (2000) J. Biol. Chem. 275, 19121-19131[Abstract/Free Full Text]
34. Mastrangelo, P., Serpell, L., Dafforn, T., Lesk, A., Fraser, P., and Westaway, D. (2002) FEBS Lett. 532, 21-24[CrossRef][Medline] [Order article via Infotrieve]
35. Wong, B. S., Liu, T., Paisley, D., Li, R., Pan, T., Chen, S. G., Perry, G., Petersen, R. B., Smith, M. A., Melton, D. W., Gambetti, P., Brown, D. R., and Sy, M. S. (2001) Mol. Cell Neurosci. 17, 768-775[CrossRef][Medline] [Order article via Infotrieve]
36. Aronoff-Spencer, E., Burns, C. S., Avdievich, N. I., Gerfen, G. J., Peisach, J., Antholine, W. E., Ball, H. L., Cohen, F. E., Prusiner, S. B., and Millhauser, G. L. (2000) Biochemistry 39, 13760-13771[CrossRef][Medline] [Order article via Infotrieve]
37. Kramer, M. L., Kratzin, H. D., Schmidt, B., Romer, A., Windl, O., Liemann, S., Hornemann, S., and Kretzschmar, H. (2001) J. Biol. Chem. 276, 16711-16719[Abstract/Free Full Text]
38. Jackson, G. S., Murray, I., Hosszu, L. L., Gibbs, N., Waltho, J. P., Clarke, A. R., and Collinge, J. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 8531-8535[Abstract/Free Full Text]
39. Hasnain, S. S., Murphy, L. M., Strange, R. W., Grossmann, J. G., Clarke, A. R., Jackson, G. S., and Collinge, J. (2001) J. Mol. Biol. 311, 467-473[CrossRef][Medline] [Order article via Infotrieve]
40. Cereghetti, G. M., Schweiger, A., Glockshuber, R., and Van Doorslaer, S. (2001) Biophys. J. 81, 516-525[Abstract/Free Full Text]
41. Spiro, T. G., and Saltman, P. (1969) in Structure and Bonding (Hemmerich, P. , Jorgensen, C. K. , Neilands, J. B. , Nyholm, R. S. , Reinen, D. , and Williams, R. J. P., eds), Vol. 6 , pp. 117-156, Springer-Verlag, New York
42. Lau, S. J., and Sarkar, B. (1971) J. Biol. Chem. 246, 5938-5943[Abstract/Free Full Text]
43. Linder, M. C., and Hazegh-Azam, M. (1996) Am. J. Clin. Nutr. 63, 797S-811S[Abstract]
44. Wong, W. Y., Flik, G., Groenen, P. M., Swinkels, D. W., Thomas, C. M., Copius-Peereboom, J. H., Merkus, H. M., and Steegers-Theunissen, R. P. (2001) Reprod. Toxicol. 15, 131-136[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.